Comment
Author: Admin | 2025-04-28
Labeling): Severe renal failure (CrCl Dosage and AdministrationDosing: AdultCalcium nephrolithiasis (off-label use): Oral: 2.5 mg once daily (AUA [Pearle 2014])Edema: Oral: Initial: 2.5 mg daily; if inadequate response after 1 week, may increase dose to 5 mg daily. Note: There is little therapeutic benefit to increasing the dose >5 mg daily; there is, however, an increased risk of electrolyte disturbances.Hypertension: Oral: Initial: 1.25 mg once daily; titrate as needed every 4 weeks up to 5 mg once daily. Usual dosage range: 1.25 to 2.5 mg once daily (ACC/AHA [Whelton 2017])Dosing: GeriatricRefer to adult dosing.AdministrationOral: May be administered without regard to meals (Caruso 1983); however, administration with food or milk may decrease GI adverse effects. Administer early in day to avoid nocturia. Dietary ConsiderationsMay be taken without regard to meals (Caruso 1983); however, administration with food or milk may to decrease GI adverse effects. StorageStore at 20°C to 25°C (68°F to 77°F). Indapamide Images indapamide 1.25 mg indapamide 2.5 mg indapamide 2.5 mg indapamide 1.25 mg indapamide 2.5 mg indapamide 2.5 mg Drug InteractionsAjmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. Monitor therapyAlcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide and Thiazide-Like Diuretics. Monitor therapyAlfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapyAllopurinol: Thiazide and Thiazide-Like Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol. Monitor therapyAmifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered. Consider therapy modificationAminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). Avoid combinationAminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Monitor therapyAmphetamines: May diminish the antihypertensive effect of Antihypertensive Agents. Monitor therapyAngiotensin-Converting Enzyme Inhibitors:
Add Comment